Conference Reports for NATAP

Back

HIV Glasgow 2020, 5-8 October Virtual Meeting     Fat distribution and density in PLWH with ≥5% weight gain - (11/03/20)   Cancer, transplantation, and other immunocompromising conditions were not significantly associated with severe COVID-19 or death in hospitalized COVID-19 patients in Chicago - (10/20/20)   Integrase based first-line HIV antiretroviral treatment in the Mediterranean Resistance (MeditRes) HIV collaboration - (10/20/20)   FOSTEMSAVIR AND ETHINYL ESTRADIOL DRUG INTERACTION: CLINICAL APPLICATION FOR CO-ADMINISTRATION - (10/20/20)   MODEL-BASED APPROACH OF DOSE SELECTION AND OPTIMAL PK SAMPLING OF FOSTEMSAVIR FOR PEDIATRIC PATIENTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION - (10/20/20)   EVALUATION AND CLINICAL APPLICATION OF FOSTEMSAVIR CO-ADMINISTRATION WITH TUBERCULOSIS MEDICATIONS - (10/20/20)   FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS - (10/20/20)   CLINICAL SIGNIFICANCE OF GP120 POLYMORPHISMS, TMR IC50 FC, AND HIV-1 SUBTYPE IN BRIGHTE - (10/20/20)   Starting or switching to bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study - (10/20/20)   Long-Term Follow-Up After a Switch to Bictegravir, Emtricitabine, Tenofovir Alafenamide (B/F/TAF) from a Boosted Protease Inhibitor-Based Regimen - (10/20/20)   The clinical relevance of potential drug-drug interactions (DDIs) with bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF) -Real-world data from the German IQVIA prescription database - (10/20/20)   FACTORS ASSOCIATED WITH INTEREST IN A LONG-ACTING HIV REGIMEN: PERSPECTIVES OF PEOPLE LIVING WITH HIV, AND PHYSICIANS IN WESTERN EUROPE - (10/15/20)   Bictegravir/emtricitabine/tenofoviralafenamide(B/F/TAF)shows high efficacy in clinical study participants infected with HIV-1 subtype F - (10/15/20)   CABOTEGRAVIR + RILPIVIRINE LONG-ACTING AS HIV-1 MAINTENANCE THERAPY: ATLAS WEEK 96 RESULTS - (10/15/20)   Rapid DTG/3TC Safe and Usually Effective in US Test-and-Treat Trial - Mark Mascolini (10/15/20)   Lenacapavir resistance analysis in a phase Ib clinical proof of-concept study: Resistance to HIV Capsid Inhibitor Rare and Linked to Single Mutation - Mark Mascolini (10/15/20)   Islatravir in Combination With Doravirine Maintains HIV-1 Viral Suppression Through 96 Weeks - (10/15/20)   Associations with weight change and patient reported outcomes after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) - (10/15/20)   Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study. HIV Drug Therapy/Glasgow 2020 - HIV Raises COVID Death Risk 52% in 47,573-Person UK Study - (10/15/20)   Unmet Needs PLWH, ViiV Positive Perspectives Global Study - (10/15/20)   SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN (TBR) IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 96 WEEKS (TANGO STUDY) - (10/15/20)   A COMBINATION OF VIRAL AND PARTICIPANT FACTORS INFLUENCE VIROLOGIC OUTCOME TO LONG-ACTING CABOTEGRAVIR + RILPIVIRINE: MULTIVARIABLE AND BASELINE FACTOR ANALYSES ACROSS ATLAS, FLAIR AND ATLAS-2M PHASE 3 STUDIES - (10/15/20)   SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN (TBR) IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 96 WEEKS (TANGO STUDY) - (10/15/20)   Increased levels of immune activation and exhaustion in vertically HIV-1 infected young adults - (10/12/20)   SAFETY AND EFFICACY OF CABOTEGRAVIR + RILPIVIRINE LONG-ACTING WITH AND WITHOUT ORAL LEAD-IN: FLAIR WEEK 124 RESULTS - (10/12/20)   Frailty of Greek PLWHIV in association with clinical markers and psychological factors; Preliminary results of a nationwide study. - (10/12/20)   Multidrug Resistance Still Boosts Death Risk in 31,000-Person Italian Study - Mark Mascolini (10/12/20)   Clinically Relevant Transmitted Integrase Resistance Low in Mediterranean Countries - Mark Mascolini - (10/12/20)   Lenacapavir Resistance Analysis in a Phase 1b Proof-of-Concept Clinical Study - (10/12/20)   The clinical relevance of potential drug-drug interactions (DDIs) with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) - Real-world data from the German IQVIA prescription database - (10/12/20)   Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol (UK): a prospective observational study - (10/12/20)   Safety, Tolerability and Pharmacokinetics Following Single- and Multiple-Dose Administration of the Novel NNRTI MK-8507 With a Midazolam Interaction Arm - (10/12/20)   Lenacapavir Resistance Analysis in a Phase 1b Clinical Proof-Of-Concept Study - (10/12/20)   SINGLE DOSES OF MK-8507, A NOVEL HIV-1 NNRTI, REDUCED HIV VIRAL LOAD FOR AT LEAST A WEEK - (10/09/20)   Islatravir Plus Doravirine Maintains HIV Control Through 96 Weeks - Mark Mascolini - (10/09/20)   Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): The BICSTaR cohort - (10/09/20)   Starting or switching to bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study - (10/09/20)   Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 72 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449) - (10/09/20)   Sustained Viral Suppression After Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Among Clinical Trial Participants With Preexisting M184V/I - (10/09/20)   12-month outcome of Dolutegravir/Rilpivirine in virologically suppressed HIV-infected patients: Real-world data from the German JUNGLE cohort - (10/09/20)   Real-world data from the prospective URBAN cohort study on the use of Dolutegravir (DTG) + Lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany - (10/09/20)   FEASIBILITY, EFFICACY, AND SAFETY OF USING DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): THE STAT STUDY - (10/08/20)   EFFICACY AND SAFETY OF DOLUTEGRAVIR IN TREATMENT-NAIVE PEOPLE LIVING WITH HIV-1 STRATIFIED BY AGE (>50): META-ANALYSIS OF 48-WEEK RESULTS FROM ARIA, FLAMINGO, SINGLE, AND SPRING-2 - (10/08/20)   Persistence of antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the US - Mark Mascolini (10/08/20)   DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION- 3-YEAR RESULTS FROM THE GEMINI STUDIES - (10/08/20)   Real-word characterization of the Portuguese population living with HIV who initiated Raltegravir based-regimen between 2015 and 2017 -REALITY Study - RAL Persistence 49 Yr Olds with Comorbidities - (10/08/20)   Islatravir Selects for HIV-1 Variants in MT4-GFP Cells That Profoundly Reduce Replicative Capacity in Peripheral Blood Mononuclear Cells - (10/08/20)   Analysis of Protocol-Defined Virologic Failure Through Week 96 From a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults WithHIV-1 Infection - (10/08/20)   Long-term Treatment Efficacy and Safety Following Switch to Doravirine/ Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF): Week 144 Results of the DRIVE-SHIFT Trial - (10/08/20)   Comorbidity Rate Does Not Affect F/TAF Persistence Through 24 Months - Mark Mascolini - (10/06/20)   The relationship between smoking, current CD4, viral load and cancer in PLWH - (10/06/20)   "WHAT ABOUT ME?" THE UNMET NEEDS OF MEN WHO HAVE SEX WITH WOMEN AND DIFFERENCES IN HIV TREATMENT EXPERIENCES, PERCEPTIONS, AND BEHAVIORS BY GENDER AND SEXUAL ORIENTATION IN 25 COUNTRIES - (10/06/20)   Prevalence of pain in women living with HIV aged 45-60: associated factors and impact on patient-reported outcomes - (10/06/20)   Impact of adherence on viral suppression with bictegravir and dolutegravir (DTG) containing triple therapy in clinical practice - Mark Mascolini (10/06/20)   Merck to Present New Data from the Company's Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020 - (10/06/20)   OUTCOMES FOR WOMEN RECEIVING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE MONTHLY AND EVERY 2 MONTHS: ATLAS-2M STUDY WEEK 48 RESULTS - (10/05/20)   Highest Cancer Risk in HIV+ Current Smokers and Those With Poor HIV Control - Mark Mascolini - (10/05/20)   SUBGROUP ANALYSIS OF PATIENT-REPORTED OUTCOMES AMONG PARTICIPANTS IN 2 PHASE III CLINICAL TRIALS OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE (ATLAS AND FLAIR) - (10/05/20)   Fat Distribution and density in PLWH with ≥ 5% weight gain - (10/05/20)   Renal Safety Through 96 Weeks in a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults With HIV-1 - (10/05/20)   COMPARABILITY OF 48-WEEK EFFICACY AND SAFETY OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING EVERY 8 WEEKS TO STANDARD OF CARE IN SUPPRESSED PEOPLE LIVING WITH HIV-1 - (10/05/20)   Virologic and CD4 Responses to DTG Generally Steady With Advancing Age - Mark Mascolini (10/05/20)   GILEAD SCIENCES PRESENTS DATA FROM HIV RESEARCH AND DEVELOPMENT PROGRAMS AT HIV GLASGOW 2020 - (10/05/20)   Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020 - (10/05/20)   ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1 - (10/05/20)   Over Half in UK HIV Women's Study Report Moderate or Severe Pain - Mark Mascolini - (10/05/20)   Switch to Integrase Drug Incites BMI Gain But Perhaps Improved "Fat Quality" - Mark Mascolini (10/05/20)   ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress - (09/28/20)